Patents by Inventor Brent Morse

Brent Morse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS THAT BIND EGFR
    Publication number: 20210040181
    Abstract: The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Application
    Filed: August 19, 2020
    Publication date: February 11, 2021
    Inventors: Ray CAMPHAUSEN, Brent MORSE, Stuart EMANUEL, David FABRIZIO
  • Targeted therapeutics based on engineered proteins that bind EGFR
    Patent number: 10781247
    Abstract: The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: September 22, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray Camphausen, Brent Morse, Stuart Emanuel, David Fabrizio
  • Portable gym structure
    Patent number: 10758803
    Abstract: A portable gym structure that is light weight and allows variable arrangement is disclosed. The portable gym structure is comprised of climbing walls and feet anchors for stability. The portable gym structure has variable configurations for different ages and abilities. The portable gym structure includes climbing walls that can be used for a slide or can be interchanged to be a climbing wall with variable climbing pieces.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: September 1, 2020
    Inventor: Marvin Brent Morse
  • TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS THAT BIND EGFR
    Publication number: 20180244755
    Abstract: The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Application
    Filed: February 1, 2018
    Publication date: August 30, 2018
    Inventors: Ray CAMPHAUSEN, Brent MORSE, Stuart EMANUEL, David FABRIZIO
  • Portable Gym Structure
    Publication number: 20180229094
    Abstract: A portable gym structure that is light weight and allows variable arrangement is disclosed. The portable gym structure is comprised of climbing walls and feet anchors for stability. The portable gym structure has variable configurations for different ages and abilities. The portable gym structure includes climbing walls that can be used for a slide or can be interchanged to be a climbing wall with variable climbing pieces.
    Type: Application
    Filed: February 15, 2018
    Publication date: August 16, 2018
    Inventor: Marvin Brent Morse
  • Targeted therapeutics based on engineered proteins that bind EGFR
    Patent number: 9920108
    Abstract: The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: March 20, 2018
    Assignee: BRISTOl-MYERS SQUIBB COMPANY
    Inventors: Ray Camphausen, Brent Morse, Stuart Emanuel, David Fabrizio
  • TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS THAT BIND EGFR
    Publication number: 20160152688
    Abstract: The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Application
    Filed: November 30, 2015
    Publication date: June 2, 2016
    Inventors: Ray CAMPHAUSEN, Brent MORSE, Stuart EMANUEL, David FABRIZIO
  • Targeted therapeutics based on engineered proteins that bind EGFR
    Patent number: 9234028
    Abstract: The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: January 12, 2016
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray Camphausen, Brent Morse, Stuart Emanuel, David Fabrizio
  • TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS THAT BIND EGFR
    Publication number: 20140038893
    Abstract: The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Application
    Filed: August 1, 2013
    Publication date: February 6, 2014
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray CAMPHAUSEN, Brent MORSE, Stuart EMANUEL, David FABRIZIO
  • Targeted therapeutics based on engineered proteins that bind EGFR
    Patent number: 8524244
    Abstract: The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Grant
    Filed: February 10, 2009
    Date of Patent: September 3, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ray Camphausen, Brent Morse, Stuart Emanuel, David Fabrizio
  • TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS THAT BIND EGFR
    Publication number: 20110053842
    Abstract: The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Application
    Filed: February 10, 2009
    Publication date: March 3, 2011
    Applicant: Bristol-Myers Squibb Company
    Inventors: Ray Camphausen, Brent Morse, Stuart Emanuel, David Fabrizio